Abstract:Kawasaki disease (KD) is an acute, self-limiting, agnogenic vasculitis that occurs frequently in children below 5 years of age and mainly involves the coronary artery [[1]Baker A.L. Newburger J.W. Kawasaki disease.Circulation. 2008; 118: E110-E112Google Scholar]. It is a common condition resulting in acquired heart disease in children. KD may lead to coronary artery aneurysm or expansion, ischemic heart disease, and sudden death [[2]Ohmoto-Sekine Y. Ishihara M. Hsieh S.D. et al.Giant coronary artery aneurysms associated with Kawasaki disease detected on whole-heart magnetic resonance coronary angiographic screening.Intern. Med. 2013; 52: 977-980Google Scholar], and in some patients, it can greatly affect quality of life even in adulthood [[3]Samada K. Shiraishi H. Sato A. Momoi M.Y. Grown-up Kawasaki disease patients who have giant coronary aneurysms.World J. Pediatr. 2010; 6: 38-42Google Scholar]. Guidelines on KD state that typical KD should be diagnosed when the patient presents fever persisting for ≥5 d and more than four main clinical features [[4]Newburger J.W. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.Circulation. 2004; 110: 2747-2771Google Scholar]. However, since these clinical features may not be manifested simultaneously, especially in the case of incomplete KD (IKD), which lacks sufficient typical clinical features, the clinical diagnosis of KD is extremely difficult. Further, the serum cytokine level, the N-terminal of prohormone brain natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) levels, and erythrocyte sedimentation rate (ESR) do not differ significantly between typical KD and IKD (Fig. 1). Additionally, in this study we found that KD patients with coronary artery disease usually receive intravenous immunoglobin (IVIG) treatment later than those KD patients without coronary artery disease (median days after illness onset of initial IVIG treatment: 7.2 vs. 5.1, P = 0.000) and their fever lasts longer (median fever duration: 11.5 vs. 7.3 days, P = 0.000). This finding suggests that early diagnosis and treatment of KD are crucial for preventing the coronary artery lesions caused by KD. Therefore, the present study aimed to evaluate the value of certain laboratory indexes in the diagnosis of KD. This prospective study enrolled 658 KD patients, 300 age-matched KD-like febrile children, and 300 age-matched healthy children as controls. After thorough clinical examination, patients who met the following criteria were included: (1) age <18 years and (2) diagnosis of typical KD or IKD. Diagnosis followed the 2004 guidelines of the American Heart Association (AHA) [[4]Newburger J.W. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.Circulation. 2004; 110: 2747-2771Google Scholar]. The exclusion criteria were any heart-related diseases. Informed consent was obtained from all patients, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institution's human research committee. We certify that we have complied with the Principles of Ethical Publishing in the International Journal of Cardiology. Cytokines were measured by flow cytometry, as described previously [5Ye Q. Shao W.-X. Xu X.-J. Yang Y.-Z. The clinical application value of cytokines in treating infectious diseases.PLoS One. 2014; 9https://doi.org/10.1371/journal.pone.0098745Google Scholar, 6Ye Q. Xu X.-J. Shao W.-X. Pan Y.-X. Chen X.-J. Mycoplasma pneumoniae infection in children is a risk factor for developing allergic diseases.Sci. World J. 2014; 2014: 986527https://doi.org/10.1155/2014/986527Google Scholar]. The serum NT-proBNP concentration was measured with a Cobas e601 analyzer (Roche Diagnostics; Germany). CRP levels were measured using QuikRead Go (Finland) with the QuikRead Go CRP kits. ESR was determined using a Vital Diagnostics automatic blood sedimentation analyzer (Italy). Statistical analyses were performed using SPSS Statistics 20.0 software. Since the pathogenesis of KD is generally considered to be related to bacterial or viral infection [7Antoniadis A.P. Chatzizisis Y.S. Giannoglou G.D. Pathogenetic mechanisms of coronary ectasia.Int. J. Cardiol. 2008; 130: 335-343Google Scholar, 8Davidson J. Frank B. Tong S.H. et al.Myocardial mechanics in Kawasaki disease: relationship to degree of systemic inflammation and coronary artery dilation.Circulation. 2013; 128Google Scholar] and it usually involves the heart [[9]Ogata S. Tremoulet A.H. Sato Y. et al.Coronary artery outcomes among children with Kawasaki disease in the United States and Japan.Int. J. Cardiol. 2013; 168: 3825-3828Google Scholar], we tried to determine the value of the levels of cytokines, CRP, and NT-proBNP as well as ESR in KD diagnosis. The results showed that NT-proBNP had the highest diagnostic efficiency for KD (area under the receiver operating characteristic curve = 0.929). When the NT-proBNP level exceeded 209.5 ng/dL, its diagnosis sensitivity and specificity for KD were 89.1% and 80.1%, respectively. Sato et al. also found that NT-proBNP is a reliable marker for KD diagnosis [[10]Sato Y.Z. Molkara D.P. Daniels L.B. et al.Cardiovascular biomarkers in acute Kawasaki disease.Int. J. Cardiol. 2013; 164: 58-63Google Scholar]. Further, the laboratory indexes CRP and ESR recommended by the AHA are known to aid in KD diagnosis. Our research, however, showed that although CRP and ESR show high efficiency in KD diagnosis, they are less efficient than NT-proBNP (Table 1).Table 1ROC curve for diagnostic value of laboratory indexes for Kawasaki disease.Diagnostic indicatorsKawasaki disease (n = 658)Normal control (n = 300)P valueAUC95% CIAssociated criterionSensitivity (%)Specificity (%)NT-ProBNP (pg/dL)1386.5 (79.0 → 24,078.0)21.0 (7.0 → 71.0)0.0000.9290.884 to 0.975≥209.589.1%80.1%ESR (mm/h)92.0 (6.0 → 225.0)3.0 (1.0 → 7.0)0.0000.9110.860 to 0.962≥4087.5%76.8%CRP (mg/L)72.0 (8.0 → 154.0)8.0 (4.0 → 14.0)0.0000.8390.771 to 0.906≥3089.1%68.9%IL-2 (pg/mL)3.5 (1.0 → 67.3)5.8 (2.7 → 7.8)0.0000.6310.539 to 0.723≥2.7573.2%52.2%IL-4 (pg/mL)3.2 (1.2 → 75.4)1.4 (1.0 → 2.1)0.0000.6560.567 to 0.746≥2.9563.1%62.5%IL-6 (pg/mL)94 (3.2 → 1919.4)4.1 (1.2 → 8.5)0.0000.7000.612 to 0.787≥41.6574.8%65.0%IL-10 (pg/mL)10.0 (2.0 → 375.6)2.4 (1.3 → 3.7)0.0000.5820.489 to 0.676≥6.9562.8%54.4%TNF-α (pg/mL)2.2 (1.0 → 80.7)2.3 (1.3 → 3.1)0.6780.4610.367 to 0.555≥2.1553.3%38.3%INF-γ (pg/mL)9.8 (1.9 → 193.9)4.6 (3.3 → 7.8)0.0000.6250.533 to 0.717≥8.7562.3%60.4%P value of kawasaki disease compared with normal control group. Range and median values are represented for each group. Open table in a new tab P value of kawasaki disease compared with normal control group. Range and median values are represented for each group. At present, a single injection of 2 g/kg IVIG together with aspirin taken orally is widely used clinically to treat KD, and the incidence of coronary artery damage has been found to decrease to 3%–5% with this treatment from 20% to 25% without this treatment [[4]Newburger J.W. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.Circulation. 2004; 110: 2747-2771Google Scholar]. However, some patients do not respond to IVIG treatment. Recent statistical data have shown that 20%–30% of KD patients do not respond to IVIG treatment which is quite higher than the 3%–5% counted a decade ago. The proportion of patients who did not respond to the first round of IVIG in the present study was 19.1%, and it increased year on year during follow-up. Moreover, non-responders had a longer total duration of fever and a higher incidence of coronary artery lesions than responders. Therefore, the early recognition and effective treatment of non-responsive KD are significant challenges and research focus. In our study we found significant differences in the NT-proBNP levels between IVIG-responsive KD patients and IVIG non-responsive KD patients (P = 0.015). When NT-proBNP ≥3100.1 pg/dL, its sensitivity in diagnosing IVIG non-responsive KD was only 53%, but its specificity was high, at 85.7%. Therefore, adoption of further rescue therapy for non-responsive patients would be an effective measure to shorten the disease course and reduce the incidence of coronary artery lesions. Clinically, few specific laboratory indexes are available to evaluate the effects of KD therapy; alleviation of clinical symptoms seems to be the main indicator of therapeutic efficacy. In this study we found that ESR does not decline but in fact increases slightly during the recovery phase of KD, and it therefore cannot be used as an index of therapeutic efficacy. However, since CRP and NT-proBNP levels reduce rapidly when patients' conditions improve, these may be useful as indexes of therapeutic efficacy for KD patients. In conclusion, NT-proBNP is useful for KD diagnosis, prediction of IVIG treatment sensitivity, and evaluation of treatment effects. However, this marker is not a specific index for KD, and its levels may increase significantly in other heart-related diseases. Thus, further investigations are needed to better examine its application. None of the authors has any conflict of interest to declare.

Retreatment and risk factors of IVIG nonresponsiveness

The prediction and treatment for intravenous immunoglobulin resistant Kawasaki disease

Center of Diagnosis and Treatment of Intravenous Immunoglobulin-Refractory Kawasaki Disease

Risk Factors of Intravenous Immunoglobulin Resistance in Children with Kawasaki Disease: A Meta-Analysis of Case-Control Studies

A new model to predict intravenous immunoglobin-resistant Kawasaki disease.

Evaluation Of Intravenous Immunoglobulin Resistance And Coronary Artery Lesions In Relation To Th1/Th2 Cytokine Profiles In Patients With Kawasaki Disease

Do cytokines correlate with refractory Kawasaki disease in children?

A Multicenter Study of Intravenous Immunoglobulin Non-response in Kawasaki Disease

Clinical Features in Patients With Intravenous Immunoglobin Resistant Kawasaki Disease

Reverse regulation of soluble receptor for advanced glycation end products and proinflammatory factor resistin and S100A12 in Kawasaki disease

Value of the N-terminal of Prohormone Brain Natriuretic Peptide in Diagnosis of Kawasaki Disease

Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8+ T cell activation in Kawasaki disease.

[Comparison of Efficacy among Early, Conventional and Late Intravenous Gamma Globulin Treatment of Kawasaki Disease].

Effectiveness of Initial Corticosteroid Treatment in Kawasaki Disease Children Suspected to be IVIG Resistant

Risk Factors and Predictive Models for Intravenous Immunoglobulin Resistance in Children with Recurrent Kawasaki Disease

A Meta-analysis of medication for intravenous immunoglobulin resistant Kawasaki disease

A Meta-Analysis of Re-Treatment for Intravenous Immunoglobulin-Resistant Kawasaki Disease

Clinical Analysis of Intravenous Immunoglobulin in the Patients with Kawasaki Disease

Randomized Trial of Different Initial Intravenous Immunoglobulin Regimens in Kawasaki Disease

Prediction of Intravenous Immunoglobulin Resistance in Kawasaki Disease in Children